Q2 2026 Neuronetics Inc Earnings Call

August 11, 2026

Operator: Good day and thank you for standing by. Welcome to the Neuronetics report Q2 2026 financial and operating results conference call. At this time, all participants are on a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising that your hand is raised. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Mike Vallie from ICR Healthcare. Please go ahead.

Speaker #1: After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone; you will then hear an automated message advising that your hand is raised.

Speaker #1: Please be advised that today's conference is being recorded. I would now like to hand the conference over to our first speaker today, Mike Valley from ICR Healthcare.

Speaker #1: Please go ahead.

Speaker #2: Good morning, and thank you for joining us for the Neuronetics second quarter 2026 conference call. Joining me on today's call are the Neuronetics President and Chief Executive Officer Dan Reavers, and the company's recently appointed Chief Financial Officer Nir Nayor.

Mike Vallie: Good morning, and thank you for joining us for the Neuronetics Q2 2026 conference call. Joining me on today's call are the Neuronetics President and Chief Executive Officer, Dan Reuvers, and the company's recently appointed Chief Financial Officer, Nir Naor. Before we begin, I would like to caution listeners that certain information discussed by management during this conference call will include forward-looking statements covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements related to our business, strategy, financial and revenue guidance, and other operational issues and metrics. Actual results can differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business.

Speaker #2: Before we begin, I would like to caution listeners that certain information discussed by management during this conference call will include forward-looking statements covered under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995, including statements related to our business strategy, financial and revenue guidance, and other operational issues and metrics.

Speaker #2: Actual results can differ materially from those stated or implied by these forward-looking statements, due to risks and uncertainties associated with the company's business. For a discussion of risks and uncertainties associated with Neuronetics business, I encourage you to review the company's filings with the Securities and Exchange Commission, including the company's annual report on Form 10-K, which was filed in March; and the company's quarterly report on Form 10-Q for the quarter ending June 30, 2026.

Mike Vallie: For a discussion of risks and uncertainties associated with Neuronetics business, I encourage you to review the company's filings with the Securities and Exchange Commission, including the company's annual report on Form 10-K, which was filed in March, and the company's quarterly report on Form 10-Q for the quarter ending 30 June 2026. The company disclaims any obligation to update any forward-looking statements made during the course of this call, except as required by law. During the call, we will also discuss certain information on a non-GAAP basis, including EBITDA. Management believes that non-GAAP financial information, taken in conjunction with U.S. GAAP financial measures, provides useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of trends in our operating results.

Speaker #2: The company disclaims any obligation to update any forward-looking statements made during the course of this call, except as required by law. During the call, we'll also discuss certain information on a non-GAAP basis, including EBITDA.

Speaker #2: Management believes that non-GAAP financial information, taken in conjunction with U.S. GAAP financial measures, provides useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of trends in our operating results.

Speaker #2: Reconciliations between U.S. GAAP and non-GAAP results are presented in the tables accompanying our press release, which can be viewed on our website. With that, it's my pleasure to turn the call over to Neuronetics President and Chief Executive Officer, Dan Reaves.

Mike Vallie: Reconciliations between U.S. GAAP and non-GAAP results are presented in the tables accompanying our press release, which can be viewed on our website. With that, it is my pleasure to turn the call over to Neuronetics President and Chief Executive Officer, Dan Reuvers.

Speaker #3: Thanks, Mike. And good morning, everyone. Thank you for joining us. I'll walk you through the quarter and each side of the business, and then I'll turn it to Nir to cover the financials in greater detail.

Dan Reuvers: Thanks, Mike, and good morning, everyone. Thank you for joining us. I will walk you through the quarter and each side of the business, and then I will turn it to Nir to cover the financials in greater detail. Then I will come back with how we are thinking about the rest of the year before opening it up for questions. Having now spent several months in the role, meeting with customers, spending time in our clinics, and working alongside our field team, I have gained a clear view of where the business is performing and where opportunities exist. I am pleased to report the second quarter began to reflect our steady execution against the goals I cited last quarter. Total revenue was $41.6 million, up approximately 9% versus the second quarter of last year. The results reflect the continued strength of Greenbrook and some early impacts of our NeuroStar TMS go-to-market pilot.

Speaker #3: Then I'll come back with how we're thinking about the rest of the year before opening it up for questions. Having now spent several months in the role, meeting with customers, spending time in our clinics, and working alongside our field team, I've gained a clearer view of where the business is performing and where opportunities exist.

Speaker #3: I'm pleased to report the second quarter began to reflect our steady execution against the goals I cited last quarter. Total revenue was $41.6 million, up approximately 9% versus the second quarter of last year.

Speaker #3: The results reflect the continued strength of Greenbrook and some early impacts of our NeuroStar TMS go-to-market pilot. Importantly, we began to show meaningful progress towards profitability and reduced our cash burn significantly.

Dan Reuvers: Importantly, we began to show meaningful progress towards profitability and reduced our cash burn significantly. Starting with NeuroStar, total worldwide NeuroStar revenue was $14.7 million. On the capital side, we had a strong quarter. This reflected an encouraging early reception to our second quarter go-to-market pilot, including a deliberate change in how we compete for customers. For most of our history, we offered essentially one way to work with us, a treatment session model built around a high-touch partnership between Neuronetics and our customer. It is a model we believe in and one that continues to set us apart with NeuroStar customers performing almost twice as many treatments per chair as the competitive landscape. A velocity improvement that directly reflects our unparalleled support. As the TMS market matured, we have seen that customers value different levels of support. Some want that full partnership.

Speaker #3: Starting with NeuroStar, total worldwide NeuroStar revenue was $14.7 million. On the capital side, we had a strong quarter. This reflected an encouraging early reception, to our second quarter go-to-market pilot.

Speaker #3: Including a deliberate change in how we compete for customers. For most of our history, we offered essentially one way to work with us: a treatment session model built around a high-touch partnership between Neuronetics and our customer.

Speaker #3: It's a model we believe in, and one that continues to set us apart, with NeuroStar customers performing almost twice as many treatments per chair as the competitive landscape—a velocity improvement that directly reflects our unparalleled support.

Speaker #3: But as the TMS markets matured, we've seen that customers value different levels of support. Some want that full partnership, while others simply want to own the system outright, the way they would any other piece of capital equipment.

Dan Reuvers: Others simply want to own the system outright, the way they would any other piece of capital equipment. Our prior strategy did not allow us to compete within this broader customer universe. To address this, while we are continuing to offer the treatment session model along with our comprehensive support program, we have also introduced new and different ways a customer can choose to acquire a NeuroStar system. Specifically, they can purchase one outright or opt for a lease-financed option, which allows a customer to use the system over time without a significant upfront capital commitment. For customers who elect to purchase a system, we now offer support on an à la carte basis, allowing them to select the specific elements of our clinical and operational support that they want, rather than accessing it through a treatment session model.

Speaker #3: Our prior strategy did not allow us to compete within this broader customer universe. To address this, what we're continuing to offer the treatment session support program, we've also introduced new and different ways customer can choose to acquire a NeuroStar system.

Speaker #3: Specifically, they can purchase one outright, or opt for a lease-financed option, which allows a customer to use the system over time without a significant upfront capital commitment.

Speaker #3: For customers who elect to purchase a system, we now offer support on an à la carte basis, allowing them to select the specific elements of our clinical and operational support that they want, rather than accessing it through a treatment session model.

Speaker #3: In each case, customers gain access to the same market-leading technology, and those who choose the session model retain the high-touch support that's always distinguished us.

Dan Reuvers: In each case, customers gain access to the same market-leading technology, and those who choose the session model retain the high-touch support that has always distinguished us. We introduced these approaches on a limited basis earlier this year and expanded the pilot through the second quarter. The early reception was encouraging, and we have since moved to a broader rollout. Over time, as more customers choose to own their systems, more of that value will be reflected in capital revenue, consumables, and service, and less in recurring session revenue. That shift reflects both the demand we are seeing for a capital model and our ability to compete for business that was previously out of reach. Consistent with our expectations, NeuroStar revenue was down slightly versus the prior year, with capital revenue up double digits while treatment session revenue was down double digits versus a year ago.

Speaker #3: We introduced these approaches on a limited basis earlier this year and expanded the pilot through the second quarter. The early reception was encouraging, and we have since moved to a broader rollout.

Speaker #3: Over time, as more customers choose to own their systems, more of that value will be reflected in capital revenue, consumables, and service, and lessen recurring session revenue.

Speaker #3: That shift reflects both the demand we're seeing for a capital model and our ability to compete for business that was previously out of reach.

Speaker #3: Consistent with our expectations, NeuroStar revenue was down slightly versus the prior year, with capital revenue up double digits, while treatment session revenue was down double digits versus a year ago.

Speaker #3: Almost half of the reduction in the sessions revenue reflected the continued normalization of customer inventory. Now at the lower levels, we'd expect to maintain.

Dan Reuvers: Almost half of the reduction in the sessions revenue reflected the continued normalization of customer inventory, now at the lower levels we would expect to maintain. The balance was from units no longer active. Underneath that, demand for treatment sessions remained strong within accounts that were active a year ago, with utilization up approximately 10% among them. The broader point is that TMS itself continues to grow both across the industry and within our accounts, and the decline in our session revenue reflects the change in our model, not the demand for the therapy. Ultimately, as we introduce new commercial options and we see some mix shifts, our H2 revenue may be a bit choppier, but the changes position us for renewed and sustainable growth as we enter 2027. We are also continuing to invest in the platform itself.

Speaker #3: The balance was from units no longer active. Underneath that, demand for treatment sessions remained strong, with an accounts that were active a year ago, with utilization up approximately 10% among them.

Speaker #3: The broader point is that TMS itself continues to grow, both across the industry and within our accounts, and the decline in our session revenue reflects the change in our model, not the demand for the therapy.

Speaker #3: Ultimately, as we introduced new commercial options and we see some mixed shifts, our second half revenue may be a bit choppier, but the change is position us for renewed and sustainable growth as we enter 2027.

Speaker #3: We’re also continuing to invest in the platform itself. In May, we announced a strategic collaboration with A&T Neuro to co-promote their FDA-cleared neuronavigation technology with NeuroStar. Providers are looking for tools that bring more visualization, consistency, and personalization into how they plan and deliver treatment, and this partnership lets us offer that alongside the NeuroStar system.

Dan Reuvers: In May, we announced a strategic collaboration with ANT Neuro to co-promote their FDA-cleared neuro navigation technology with NeuroStar. Providers are looking for tools that bring more visualization, consistency, and personalization into how they plan and deliver treatment, and this partnership lets us offer that alongside the NeuroStar system. We have the largest installed base of TMS systems in the country, which gives us the ability to bring innovations like this to market and scale them across the field. Moving to Greenbrook, which was the star of the quarter. The operational discipline that we have been building into the clinic business continued. Greenbrook revenue was $26.9 million, up approximately 17% year-over-year. Beyond the top-line growth at Greenbrook, our work on revenue cycle management continued to produce results, with cash collections growing even faster than revenue.

Speaker #3: We have the largest installed base of TMS systems in the country, which gives us the ability to bring innovations like this to market and scale them across the field.

Speaker #3: Moving to Greenbrook, which was the star of the quarter. The operational discipline that we've been building into the clinic business continued. Greenbrook revenue was $26.9 million, up approximately 17% year over year.

Speaker #3: Beyond the top-line growth at Greenbrook, our work on revenue cycle management continued to produce results, with cash collections growing even faster than revenue. Focusing on better qualifying patients' eligibility, cleaner claim submissions, and more efficient collections were key contributors.

Dan Reuvers: Focusing on better-qualifying patients' eligibility, cleaner claims submissions, and more efficient collections were key contributors, along with improved reimbursement rates through more effective payer contracting across both TMS and SPRAVATO. We also began using AI in the insurance authorization process, which has helped us reduce operating costs. This reflects the operational discipline that we have been building into these clinics, and it is converting into cash, not just billings, and we believe there is still runway ahead of us. The other lever is occupancy. These clinics carry a largely fixed cost base, so the more efficiently we can run each site and the more patients we treat, the more profitable each location becomes. That is where much of our operational focus continues to sit today.

Speaker #3: Along with improved reimbursement rates, through more effective payer contracting, across both TMS and Spravato. We also began using AI in the insurance authorization process, which has helped us reduce operating costs.

Speaker #3: This reflects the operational discipline that we've been building into these clinics. And it's converting into cash, not just billings. And we believe there's still runway ahead of us.

Speaker #3: The other lever is occupancy. These clinics carry a largely fixed cost base, so the more efficiency efficiently we can run each site, and the more patients we treat, the more profitable each location becomes.

Speaker #3: That's where much of our operational focus continues to sit today. With available capacity, we're closely examining our sales methods, including number of field reps, direct-to-consumer ad spend, and peer-to-peer education events, attempting to improve referrals while doing so with the most efficient patient acquisition cost.

Dan Reuvers: With available capacity, we are closely examining our sales methods, including number of field reps, direct-to-consumer ad spend, and peer-to-peer education events, attempting to improve referrals while doing so with the most efficient patient acquisition cost. This too remains a meaningful incremental profitability driver. Before we move on, I wanted to provide an update on changes to our senior leadership team. As you might imagine, I spent a fair amount of time in my first 100 days evaluating our leadership team and structure. As a result, I made some changes to our leadership team, including reducing executive headcount and flattening our structure. This should allow us to get and stay closer to the details of the business. Some of the key changes include the recent appointment of Nir Naor as Chief Financial Officer.

Speaker #3: This too remains a meaningful incremental profitability driver. Before we move on, I wanted to provide an update on changes to our senior leadership team.

Speaker #3: As you might imagine, I spent a fair amount of time in my first 100 days evaluating our leadership team, and structure. As a result, I made some changes to our leadership team including reducing executive headcount and flattening our structure.

Speaker #3: This should allow us to get and stay closer to the details of the business. Some of the key changes include the recent appointment of near-newer as chief financial officer.

Speaker #3: Neer brings more than 20 years of finance experience across medical device and care delivery businesses, including at his last company, where he helped the business reach profitability and achieve positive cash flow within a year.

Dan Reuvers: Nir brings more than 20 years of finance experience across medical device and care delivery businesses, including at his last company, where he helped the business reach profitability and achieve positive cash flow within a year. That experience is directly relevant to our priorities at this stage of our business, and I'm confident he'll be a key thought partner as we execute on our priorities. We also promoted Cory Anderson to Executive Vice President and General Manager of Greenbrook. Cory's been with us more than five years, overseeing both our technology and clinical data efforts, as well as leading the commercial readiness efforts of psychedelics with our partners at Compass Pathways.

Speaker #3: That experience is directly relevant to our priorities at this stage of our business, and I'm confident he'll be a key thought partner as we execute on our priorities.

Speaker #3: We also promoted Cori Anderson to executive vice president and general manager of Greenbrook. Cori's been with us more than five years overseeing both our technology and clinical data efforts.

Speaker #3: As well as leading the commercial readiness efforts of psychedelics with our partners at Compass Pathways. Putting a dedicated leader with a rich understanding of the interventional psychiatry space as the head of Greenbrook reflects its importance to our future, and the types of initiatives that will help us continue to drive growth in that part of the business.

Dan Reuvers: Putting a dedicated leader with a rich understanding of the interventional psychiatry space as the head of Greenbrook reflects its importance to our future and the types of initiatives that will help us continue to drive growth in that part of the business. In June, we appointed Rob Greene as Senior Vice President of Sales. Rob spent his career leading commercial organizations across healthcare and medical technology, including in capital equipment and service. As we roll out new commercial models for NeuroStar, Rob's experience will be central to executing that strategy. Separately, we consolidated roles in marketing and operations, and Andy Macan will be stepping down as Chief Legal Officer later this month. With this team in place, we're well-positioned to execute our strategy and the priorities that we're reviewing this morning.

Speaker #3: And in June, we appointed Rob Green as Senior Vice President of Sales. Rob has spent his career leading commercial organizations across healthcare and medical technology.

Speaker #3: Including in capital equipment and service. As we roll out new commercial models for NeuroStar, Rob's experience will be central to executing that strategy. Separately, we consolidated roles in marketing and operations and Andy McCann will be stepping down as chief legal officer later this month.

Speaker #3: With this team in place, we're well positioned to execute our strategy and the priorities that we're reviewing this morning. Stepping back, we moved forward this quarter on what matters most: competing for NeuroStar customers who were previously out of reach, running our Greenbrook clinics more efficiently, and advancing our goals towards profitability and cash generation.

Dan Reuvers: Stepping back, we moved forward this quarter on what matters most, competing for NeuroStar customers who were previously out of reach, running our Greenbrook clinics more efficiently, and advancing our goals towards profitability and cash generation. With that, I'll turn it over to Nir to take you through the financials, and I'll come back with our outlook for the rest of the year. Nir?

Speaker #3: With that, I'll turn it over to Neer to take you through the financials, and I'll come back with our outlook for the rest of the year.

Speaker #3: Neer?

Speaker #2: Thank you, Dan, and good morning, everyone. Let me start with a few thoughts on why I joined, and then walk you through the quarter.

Nir Naor: Thank you, Dan, and good morning, everyone. Let me start with a few thoughts on why I joined and then walk you through the quarter. I came to Neuronetics because I saw a business with a strong core, leading technology, and a national clinical network, as well as a clear opportunity to improve how it converts that into profitability and cash. That is what I've spent my career doing, and that is what I intend to focus on here. To our financials, unless otherwise noted, all performance comparisons are being made to Q2 2026 versus Q2 2025. Total revenue in Q2 was $41.6 million, an increase of 9.1% compared to revenue of $38.1 million in Q2 2025. The increase in revenue was primarily driven by higher Greenbrook revenue.

Speaker #2: I came to Neuronetics because I saw a business with a strong core leading technology and a national clinic network, as well as a clear opportunity to improve how it converts that into profitability and cash.

Speaker #2: That is what I've spent my career doing, and that is what I intend to focus on here. And to our financials. Unless otherwise noted, all performance comparisons are being made to the second quarter of 2026 versus the second quarter of 2025.

Speaker #2: Total revenue in the second quarter was $41.6 million, an increase of 9.1% compared to revenue of $38.1 million in the second quarter of 2025.

Speaker #2: The increase in revenue was primarily driven by higher Greenbrook revenue. With the commercial model updates that Dan mentioned in his comments, we intend to update our financial reporting on a go-forward basis to better align with the relevant operational metrics.

Nir Naor: With the commercial model update that Dan mentioned in his comments, we intend to update our financial reporting on a go-forward basis to better align with the relevant operational metrics. As customers move between owning a system, financing one, purchasing support on an à la carte basis, or opting for the traditional session model, the split between capital and treatment session revenue no longer reflects the business in a consistent manner. We plan to manage the total growth of the NeuroStar franchise. With a host of contributing revenue lines, such as sessions, capital, lease, service, consumables, and others, comparisons versus the past become less relevant for us. As a result, we will look at our NeuroStar business more holistically and intend to report it as a single revenue line going forward.

Speaker #2: As customers move between owning a system financing one, purchasing support on an à la carte basis, or opting for the traditional session model, the split between capital and treatment session revenue no longer reflects the business in a consistent manner.

Speaker #2: We plan to manage the total growth of the NeuroStar franchise. With a host of contributing revenue lines such as sessions, capital, lease, service, consumables, and others, comparisons versus the past become less relevant for us.

Speaker #2: As a result, we will look at our NeuroStar business more holistically and intend to report it as a single revenue line going forward. Accordingly, total revenue from our NeuroStar business was $14.7 million in the second quarter of 2026, a decrease of 2.7%.

Nir Naor: Accordingly, total revenue from our NeuroStar business was $14.7 million in Q2 2026, a decrease of 2.7%. For context, our session revenue was down double digits and our capital sales were up double digits. Greenbrook revenue was $26.9 million, a 16.8% increase. The results were driven by strong continued provider growth and overall pricing improvements. Gross margin was 61.1% in Q2 2026, compared to 46.6% in the prior year. This was a function of mix and our improving revenue cycle management efforts. Operational expenses during the quarter were $22.7 million, a decrease of $3.1 million or 12% compared to $25.8 million in Q2 2025. This was largely due to lower general and administrative expenses and lower sales in marketing expenses. Continued cost efficiency measures were one of the key drivers for that change.

Speaker #2: For context, our session revenue was down double digits, and our capital sales were up double digits. Greenbrook revenue was $26.9 million, a 16.8% increase.

Speaker #2: The results were driven by strong continuous provider growth and overall pricing improvement. Gross margin was $51.1% in the second quarter of 2026 compared to $46.6% in the prior year.

Speaker #2: This was a function of mix and our improving revenue cycle management efforts. Operational expenses during the quarter were $22.7 million, a decrease of $3.1 million, or 12%, compared to $25.8 million in the second quarter of 2025.

Speaker #2: This was largely due to lower general and administrative expenses, as well as lower sales and marketing expenses. Continued cost efficiency measures were one of the key drivers for that change.

Nir Naor: Net loss for the quarter was -$3.4 million, or -$0.05 per share, compared to a net loss of -$10.1 million, or -$0.15 per share in the prior year. Adjusted EBITDA was +$0.3 million as compared to -$5.6 million in the prior year, an improvement of $5.9 million. Moving to the balance sheet and cash flow. As of 30 June, total cash was $25 million, consisting of cash equivalents, and restricted cash as compared to $19 million as of 31 March 2026. Cash used by operations and investing in Q2 was -$1.4 million. This compares to cash used from operations and investing of -$3.8 million in Q2 2025. During the quarter, we also raised $7.6 million in net proceeds through our at-the-market equity offering. Now, turning to guidance.

Speaker #2: Net loss for the quarter was $3.4 million, or $0.05 per share, compared to a net loss of $10.1 million, or $0.15 per share, in the prior year.

Speaker #2: Adjusted EBITDA was positive 0.3 million as compared to negative 5.6 million in the prior year, an improvement of 5.9 million. Moving to the balance sheet and cash flow.

Speaker #2: As of June 30th, total cash was $25 million, consisting of cash, cash equivalents, and restricted cash, as compared to $19 million as of March 31st, 2026.

Speaker #2: Cash used by operations and investing in the second quarter was $1.4 million. This compares to cash used from operations and investing of $3.8 million in Q2 of 2025.

Speaker #2: During the quarter, we also raised $7.6 million in net proceeds through our at-the-market equity offering. Now, turning to guidance, we're narrowing our total revenue range to $160 million to $164 million, compared to prior guidance of $160 million to $166 million.

Nir Naor: We are narrowing our total revenue range to $160 to $164 million, compared to prior guidance of $160 to $166 million. We now expect gross margin range to be between 48% and 50%, compared to prior guidance of 47% to 49%. We are lowering our OpEx guidance to $95 to $100 million versus our prior guidance of $100 to $105 million. The majority of this change is driven by a decreased expectation of share-based compensation. Since share-based compensation fluctuates significantly, is a non-cash component, and is difficult to forecast going forward, we are going to guide to OpEx excluding share-based compensation. On this basis, we would expect this number to be $91 to $96 million for the year. Our current estimate of share-based compensation is $4 million for the year.

Speaker #2: We now expect gross margin range to be between 48% and 50% compared to prior guidance of 47% to 49%. We're lowering our OPEX guidance to $95 to $100 million.

Speaker #2: Versus our prior guidance of $100 to $105 million. The majority of this change is driven by a decreased expectation of share-based compensation. Since share-based compensation fluctuates significantly, it's a non-cash component and is difficult to forecast going forward.

Speaker #2: We're going to guide to OPEX, excluding share-based compensation. On this basis, we would expect this number to be $91 million to $96 million for the year.

Speaker #2: Our current estimate of share-based compensation is $4 million for the year. We're also updating our cash flow guidance to include both cash flow from operations and cash flow from investing as we consider the sum a more representative view of the company's organic cash utilization and estimated to be in the range of negative 10 and a half million dollars to negative 14 and a half million for the full year.

Nir Naor: We are also updating our cash flow guidance to include both cash flow from operations and cash flow from investing, as we consider this sum a more representative view of the company's organic cash utilization and estimate it to be in the range of negative $10.5 million to negative $14.5 million for the full year. This is compared to our prior guidance of cash flow from operations only in the range of negative $13 million to negative $17 million. We continue to target limited net cash utilization from operations and investing in the H2 of the year. In summary, this was a quarter of solid financial progress. We grew revenue, improved our margins, reduced our cash burn, and strengthened our balance sheet, all while continuing to invest in the growth of the business. Our focus is on converting that progress into sustained profitability and positive operating cash flow.

Speaker #2: This is compared to our prior guidance of cash flow from operations only in the range of negative 13 million dollars to negative 17 million.

Speaker #2: We continue to target limited net cash utilization from operations and investing in the second half of the year. In summary, this was a quarter of solid financial progress.

Speaker #2: We grew revenue, improved our margins, reduced our cash burn, and strengthened our balance sheet, all while continuing to invest in the growth of the business.

Speaker #2: Our focus is on converting that progress into sustained profitability and positive operating cash flow. With that, I will turn it back to Dan for his closing remarks.

Nir Naor: With that, I will turn it back to Dan for his closing remarks.

Speaker #3: Thanks, Neer. Let me close with a few thoughts on where we go from here. During the quarter, we continued our collaboration with Compass Pathways to prepare for the anticipated commercial launch of their psychedelic therapeutic for treatment-resistant depression, or TRD.

Dan Reuvers: Thanks, Nir. Let me close with a few thoughts on where we go from here. During the quarter, we continued our collaboration with Compass Pathways to prepare for the anticipated commercial launch of their psychedelic therapeutic for treatment-resistant depression, or TRD. We also shared the stage with them at an investor panel last month to continue to educate the investor community about the potential market dynamics with a new treatment option for providers to prescribe for TRD patients. With their recent phase III extended durability data readout, our enthusiasm for the opportunity continues to grow. The regulatory path is Compass to run, and I am not going to get ahead of it. But therapies like this, when they come to market, will require exactly the kind of delivery platform that we already operate.

Speaker #3: We also shared the stage with them at an investor panel last month to continue to educate the investor community about the potential market dynamics with a new treatment option for providers to prescribe for TRD patients.

Speaker #3: With their recent phase three extended durability data readout, our enthusiasm for the opportunity continues to grow. The regulatory path is compass to run.

Speaker #3: And I'm not going to get ahead of it, but therapies like this, when they come to market, will require exactly the kind of delivery platform that we already operate.

Speaker #3: In-office drug delivery and monitoring, REMS programs, trained clinical staff, and the benefits investigation and prior authorization infrastructure that we run every day for Spravato.

Dan Reuvers: In-office drug delivery and monitoring, REMS programs, trained clinical staff, and the benefits investigation and prior authorization infrastructure that we run every day for SPRAVATO. As new psilocybin treatments become available, they will need places equipped to deliver them safely and at scale. Greenbrook's experience, scale, and available capacity positions us as an early leader in that space as we look forward to providing the most comprehensive menu of interventional psychiatry options for patients. More broadly, our priorities for the rest of the year are clear. We will continue expanding how we compete within the TMS space with NeuroStar, keep driving operational discipline and cash generation at Greenbrook while seeking to help even more patients, expanding our occupancy, and positioning ourselves for the opportunities ahead in interventional psychiatry. Ultimately, we intend to be the destination of choice for the psychiatry community looking for the most effective treatment interventions for their patients.

Speaker #3: As new psilocybin treatments become available, they'll need places equipped to deliver them safely and at scale. Greenbrook's experience, scale, and available capacity positions us as an early leader in that space as we look forward to providing the most comprehensive menu of interventional psychiatry options for patients.

Speaker #3: More broadly, our priorities for the rest of the year are clear. We'll continue expanding how we compete within the TMS space with NeuroStar, keep driving operational discipline and cash generation at Greenbrook, while seeking to help even more patients by expanding our occupancy and positioning ourselves for the opportunities ahead in interventional psychiatry.

Speaker #3: Ultimately, we intend to be the destination of choice for the psychiatry community looking for the most effective treatment interventions for their patients. We have real work in front of us, but we have the team, the resources, and the momentum to see it through.

Dan Reuvers: We have real work in front of us, but we have the team, the resources, and the momentum to see it through. Before I close, I will note that earlier this month, we announced a constructive understanding with one of our largest shareholders, reflecting a shared commitment to maximizing long-term value for our shareholders. The board and I welcome that alignment, and it reinforces the focus we all share on executing the priorities I have laid out this morning. I want to thank our employees for a hard-fought quarter and for the work that they do every day on behalf of the patients that we serve, and our shareholders for their continued support. With that, operator, we are ready to open the line for questions.

Speaker #3: Before I close, I'll note that earlier this month we announced a constructive understanding with one of our largest shareholders, reflecting a shared commitment to maximizing long-term value for our shareholders.

Speaker #3: The board and I welcome that alignment, and it reinforces the focus we all share on executing the priorities I've laid out this morning. I want to thank our employees for a hard-fought quarter, and for the work that they do every day on behalf of the patients that we serve, and our shareholders for their continued support.

Speaker #3: With that, operator, we're ready to open the line for questions.

Speaker #1: Thank you. Ladies and gentlemen, as a reminder, to ask a question at this time you will need to press star 1-1 on your telephone and wait for your name to be announced.

Operator: Thank you. Ladies and gentlemen, as a reminder, to ask a question at this time, you will need to press star one one on your telephone and wait for your name to be announced. To withdraw your question, simply press star one one again. Please stand by while we compile the Q&A roster. The first question coming from the line of Bill Plovanic with Canaccord. Your line is now open.

Speaker #1: To withdraw your question, simply press star one-one again. Please stand by while we compile the Q&A roster. Now, the first question is coming from the line of Bill Pavlonic with Kana Court.

Speaker #1: Yellen is now open.

Speaker #4: Hey, great. Thanks. Good morning. Can you hear me okay?

Bill Plovanic: Hey, great. Thanks. Good morning. Can you hear me okay?

Speaker #5: Yep. Good morning, Bill.

Dan Reuvers: Yep. Morning, Bill.

Bill Plovanic: Good morning. First of all, congratulations on a solid quarter, definitely improving the cash flow. I am going to focus on the future rather than the past. In terms of Greenbrook, as you are leaning into this really service offering for all these new psychedelics coming to market, I was wondering if you could help us understand just with the Greenbrook footprint, as you go to optimize those, one, how many rooms are typically available on average per site? Two, as you become more cash-generating, could we expect you to start opening more facilities or expanding the existing facilities? My understanding is the Compass product is like a six-hour versus maybe SPRAVATO with about two hours of observation. I am trying to, as new drugs come to market, they are going to have different requirements. And how do you address those capacity issues and balance that against revenue?

Speaker #4: Good morning. First of all, congratulations on a solid quarter—definitely improving the cash flow. I'm going to focus on the future rather than the past.

Speaker #4: In terms of Greenbrook, is your leaning into this really service offering for all these new psychedelics coming to market? I was wondering if you could help us understand just with the Greenbrook footprint, as you go to optimize those.

Speaker #4: One, how many rooms are typically available on average per site? Two, as you become more cash-generating, could we expect you to start opening more facilities or expanding the existing facilities?

Speaker #4: My understanding is the Compass product is like a six-hour, versus maybe Spravato at about two hours of observation. So I'm trying to—as new drugs come to market, they're going to have different requirements—and how do you address those capacity issues and balance that against revenue?

Speaker #4: But really, it's on the Greenbrook and just leaning in there. Thanks.

Bill Plovanic: But really, it is on the Greenbrook and just leaning in there. Thanks.

Speaker #5: Yeah, good question. Thanks, Bill. So, I think first of all—I'll talk about psychedelics in a minute—but I think that, initially, there's a lot of runway that continues to be available to us simply in improving the capacity that's available within so many of our sites.

Dan Reuvers: Yeah. Good question. Thanks, Bill. I think, first of all, I will talk about psychedelics in a minute, but I think that initially, there is a lot of runway that continues to be available to us simply in improving the capacity that is available within so many of our sites. We have got a fair amount of fixed costs, as you know, and we have talked about having available capacity as much as 40% that is still not consumed. So filling those chairs with patients that can benefit from our therapies is a top priority. And I think we have a lot of improvement to occur, even while we are waiting for the psychedelics to be introduced. That said, we think about it more as units of time and available capacity. A lot of these rooms where we treat patients for SPRAVATO can quite easily be converted to also administer psychedelics like COMP360.

Speaker #5: So, as you know, we've got a fair amount of fixed costs, and we've talked about having available capacity—as much as 40%—that's still not consumed.

Speaker #5: So filling those chairs with patients that can benefit from our therapies is a top priority. And I think we have a lot of improvement to occur even while we're waiting for the psychedelics to be introduced.

Speaker #5: That said, we think about it more as units of time and available capacity. A lot of these rooms where we treat patients for Spravato can quite easily be converted to also administer psychedelics like Compass 360.

Speaker #5: So I think that we've already got the capacity in the rooms, and it's a matter of making sure that we're filling these to better capacity, which is an opportunity for growth that we have even before some of the psychedelics come available.

Dan Reuvers: I think that we have already got the capacity in the rooms, and it is a matter of making sure that we are filling these to better capacity, which is an opportunity for growth that we have, even before some of the psychedelics come available. And then as they do, we have been putting a lot of energy into making sure that we are being thoughtful about how we would schedule those varying treatments. As we know, TMS is a matter of minutes. It is a couple of hours for SPRAVATO, and to your point, probably closer to six hours for COMP360 in varying sequences for some of the other therapeutics to come later. We are starting to use AI for scheduling to optimize how we can make sure that we do that in the most productive way. I think there is a lot of opportunity for us to continue to fill that capacity.

Speaker #5: And then as they do, we have been putting a lot of energy into making sure that we're being thoughtful about how we would schedule those varying treatments as we know TMS is a matter of minutes.

Speaker #5: It's a couple of hours for Spravato and, to your point, probably closer to six hours for Compass 360, in varying sequences for some of the other therapeutics to come later.

Speaker #5: We're starting to use AI for scheduling to optimize how we can make sure that we do that in the most productive way. So I think there's a lot of opportunity for us to continue to fill that capacity, and once we do—once we start to get closer to that and we need more space—certainly, more sites or expanding those footprints is well within our roadmap.

Dan Reuvers: Once we do, once we start to get closer to that and we need more space, certainly more sites or expanding those footprints is well within our roadmap. But initially, I think there's so much unused capacity, we're really focused there first, and then sequentially, there will be an opportunity for us to look at expansion.

Speaker #5: But initially, I think there's so much unused capacity. We're really focused there first, and then sequentially, there will be an opportunity for us to look at expansion.

Speaker #4: Excellent. And if I could have one follow-up, just on you've come in and you've made a lot of you've cut a lot of costs.

Bill Plovanic: Excellent. If I could have one follow-up just on, you've come in and you've cut a lot of costs. I mean, definitely have improved the operating structure of the business. As you think of that mission from here forward with the recent announcements you've made and the changes in management, are you through kind of the bulk of the changes and here it's more incremental tweaking from a cost structure? Or just how should we think about the opportunity for further efficiency gains in the operating structure? Thanks.

Speaker #4: I mean, you definitely have improved the operating structure of the business. As you think of that mission from here forward, with the recent announcements you've made and the changes in management, are you through kind of the bulk of the changes in here?

Speaker #4: Is it more about incremental tweaking from a cost structure perspective, or how should we think about the opportunity for further efficiency gains in the operating structure?

Speaker #4: Thanks.

Speaker #5: Yeah, I think that a natural thing is sometimes we don't always look in the mirror first as executives. So, starting with the leadership ranks and trying to make sure that the structure and the people that fill the right roles was established, I feel really good about where we sit today.

Dan Reuvers: Yeah. I think that a natural thing is sometimes we don't always look in the mirror first as executives. So starting with the leadership ranks and trying to make sure that the structure and the people that fill the right roles was established, I feel really good about where we sit today. I think we've added some really good talent. I think we've redistributed some of the assignments to some really talented up-and-coming folks within the organization. So I feel like we sit quite well there. I think there's probably still opportunities for us. I think this is where having a new CFO flanking me with just a couple of weeks under his belt, he and I will have an opportunity to more comprehensively continue to examine where those additional opportunities might exist.

Speaker #5: I think we've added some really good talent. I think we've redistributed some of the assignments to some really talented, up-and-coming folks within the organization.

Speaker #5: So I think that we I feel like we sit quite well there. I think there's probably still opportunities for us. I think this is where having a new CFO flanking me with just a couple of weeks under his belt he and I will have an opportunity to more comprehensively continue to examine where those additional opportunities might exist.

Speaker #5: But organizationally, I feel like we've made a lot of progress, and I'm feeling very good about how we've anchored ourselves at this point.

Dan Reuvers: But organizationally, I feel like we've made a lot of progress, and I'm feeling very good about how we've anchored ourselves at this point.

Speaker #4: Great. Thank you.

Bill Plovanic: Great. Thank you.

Speaker #5: Thanks, Bill.

Dan Reuvers: Thanks, Bill.

Speaker #1: Thank you. Our next question in queue coming from the line of Danny Sauda with Citizens Bank. Yellen is now open.

Operator: Thank you. Our next question in queue coming from the line of Daniel Stauder with Citizens JMP. Your line is now open.

Speaker #4: Yeah, great. Thank you for the questions. Really nice quarter and, Neer, congrats on the new role, and it's great to have you on the call.

Daniel Stauder: Yeah, great. Thank you for the questions. Really nice quarter, and Nir, congrats on the new role, and it's great to have you on the call. Just on my first one, I want to make sure I am kind of understanding the NeuroStar treatment session dynamic here. So it sounds like the normalization of inventory should continue through the rest of the year, so should continue to be down, maybe with some offset from gains in capital. So just want to make sure that is the right way to be thinking about it. Then do you think this is more of a dynamic for just new customers, or do you expect a larger portion of your existing customers to transition to some of these other models and offerings that you have? Thank you.

Speaker #4: Just on my first one, I want to make sure I'm kind of understanding the NeuroStar treatment session dynamic here. So, it sounds like the normalization of inventory should continue through the rest of the year.

Speaker #4: So, should continue to be down, maybe with some offset from gains in capital. So, just want to make sure that's the right way to be thinking about it.

Speaker #4: And then do you think this is more of a dynamic for just new customers or do you expect a larger portion of your existing customers to transition to some of these other models and offerings that you have?

Speaker #4: Thank you.

Speaker #5: Yeah. Thanks, Danny. Good. Appreciate the question. I think on the sessions inventory, just to be clear, we feel like the inventories are down about as low as we would expect them to be maintained.

Dan Reuvers: Yeah. Thanks, Daniel. Appreciate the question. I think on the sessions inventory, just to be clear, we feel like the inventories are down about as low as we would expect them to be maintained. I do not see any continued inventory reductions in the back half of the year. I think we have, after Q2, I think largely equilibrated to where we think normal, sustainable inventories would be. I do not see that as much of a headwind in the back half as perhaps in Q2. I think from an existing customer standpoint, one of the things I want to make sure does not get lost is a comment I made in the prepared remarks. We know that our chairs receive almost twice as much velocity, patient velocity, as the competitive landscape.

Speaker #5: So I don't see any continued inventory reductions in the back half of the year. I think we've after the second quarter, I think largely equilibrated to where we think normal sustainable inventories would be.

Speaker #5: So I don't see that as much of a headwind in the back half as perhaps in the second quarter. I think from an existing customer standpoint, one of the things I want to make sure doesn't get lost is a comment I made in the prepared remarks.

Speaker #5: We know that our chairs receive almost twice as much velocity patient velocity as the competitive landscape. So we certainly think that a lot of the customers that have selected us did so largely because of the comprehensive support we provide and the kind of improvements it makes in their own practice.

Dan Reuvers: We certainly think that a lot of the customers that have selected us did so largely because of the comprehensive support we provide and the kind of improvements it makes in their own practice. I think that we expect that an awful, I think the majority probably, of those sessions customers who have benefited from that level of comprehensive service will continue in that vein. We will certainly offer more options, and that is what we have been talking about in our new go-to-market strategy, is we want to let the customer decide where they see the value and how they want to pay for it. I think the other point to be made is that if a new customer, for example, chose the capital route versus the traditional sessions route, they will still pay for things like service and consumables and training.

Speaker #5: So I think that we expect that an awful I think the majority probably of those sessions customers who have benefited from that level of comprehensive service will continue in that vein.

Speaker #5: We will certainly offer more options, and that's what we've been talking about in our new go-to-market strategy—we want to let the customer decide where they see the value and how they want to pay for it.

Speaker #5: So, I think the other point to be made is that if a customer—a new customer, for example—chose the capital route versus the traditional sessions route, they'll still pay for things like service, consumables, and training.

Speaker #5: And those things are currently embedded in the sessions structure. It's one of the reasons that we chose to start to report on this on a more holistic basis, because there's probably going to be some noise moving back and forth.

Dan Reuvers: Those things are currently embedded in the sessions structure. It is one of the reasons that we chose to start to report on this on a more holistic basis, because there is probably going to be some noise moving back and forth. I think that it is important to appreciate that some of the consumables, some of the service, that revenue that we have gotten has been embedded in the sessions revenue side. We are going to give customers the option to decide how they want to pay for the value that we bring. Ultimately, I think that while we will expect to open ourselves up to new socket placements with this broader go-to-market, we are also hearing that there is a big segment of our customer base that remind us why they picked us in the first place, and that is that comprehensive support that we provide.

Speaker #5: And I think that it's important to appreciate that some of the consumables, some of the service revenue that we've gotten, has been embedded in the sessions revenue side.

Speaker #5: So we're going to give customers the option to decide how they want to pay for the value that we bring. But ultimately, I think that while we will expect to open ourselves up to new socket placements with this broader go-to-market, we're also hearing that there's a big segment of our customer base that reminds us why they picked us in the first place.

Speaker #5: And that's that comprehensive support that we provide.

Daniel Stauder: No, that is great. I appreciate that. Just one quick follow-up from me. It was great to see the improvement on operating expenses and below the top line. I wanted to focus on gross margin, just that line was really strong, even with clinic revenue being the primary driver of growth and making up a larger mix of sales. Could you just give us a little bit more color on what drove that gross margin expansion here? I think you called out some pricing improvement within clinics, so any color there or just anything else on the execution would be great. Thank you.

Speaker #4: Oh, that's great. Appreciate that. And then, one quick follow-up from me. It was great to see the improvement in operating expenses, and below the top line, I wanted to focus on gross margin. That line was really strong, even with clinic revenue being the primary driver of growth and making up a larger mix of sales. So, could you just give us a little bit more color on what drove that gross margin expansion here?

Speaker #4: I think you called out some pricing improvement within clinics. So any color the execution would be great. Thank you.

Dan Reuvers: Sure. Yeah. That is certainly a high point for the quarter. As you know, we raised our guidance on gross margin for the full year, so we think that some of these improvements are durable. The good news, I think, also is that we saw support or strength in the gross margin on both the Greenbrook and the NeuroStar side. On the Greenbrook side, a lot of it has to do with improved revenue cycle management, and that is as we make sure that we are being more disciplined about patient qualification, which is good for the patient as well. They do not want to find out that they do not meet the right criteria when they are three sessions in. So that has been a focus. That leads to cleaner claims and more efficient accounts receivables.

Speaker #5: Sure. Yeah. That's certainly a high point for the quarter. And as you know, we raised our guidance on gross margin for the full year.

Speaker #5: So we think that some of these improvements are durable. And the good news, I think, also is that we saw support or strength in the gross margin on both the Greenbrook and the NeuroStar side.

Speaker #5: So on the Greenbrook side, it's a lot of it has to do with improved revenue cycle management. And that is as we make sure that we're being more disciplined about patient qualification, which is good for the patient as well.

Speaker #5: They don't want to find out that they don't meet the right criteria when they're three sessions in. So that's going to focus. That leads to cleaner claims.

Speaker #5: And more efficient accounts receivable. So all of those things mean you capture a bit better revenue on a billed dollar than we did in the past.

Dan Reuvers: All of those things mean you capture a bit better revenue on a billed dollar than we did in the past. I think those are durable, and those are clearly things that are contributing to the better gross margin on Greenbrook, along with some pricing, relative to our team's work with some of the third-party payers. On the NeuroStar side, while sessions revenue was off a bit and capital was up, I think it also points to the fact that as our mix starts to equilibrate more and it is not exclusively on the sessions side, our ASP is going up. As that growth occurs in capital, I think that can be also a sustainable good guide for us on the gross margin side. Of course, both of those considerations are embedded in our updated guidance.

Speaker #5: And I think those are durable, and those are clearly things that are contributing to the better gross margin on Greenbrook, along with some pricing relative to our team's work with some of the third-party payers.

Speaker #5: On the NeuroStar side, while sessions revenue was off a bit and capital was up, I think it also points to the fact that as our mix starts to equilibrate more, and it's not exclusively on the session side, our ASP is going up.

Speaker #5: So as that growth occurs in capital, I think that that can be also a sustainable good guy for us on the gross margin side.

Speaker #5: And of course, both of those considerations are embedded in our updated guidance.

Daniel Stauder: Great. Thank you so much for the questions.

Speaker #4: Thank you so much for the questions.

Dan Reuvers: Mm-hmm. Thank you.

Speaker #5: you.

Speaker #2: Thank you. And the final question comes from the line of Sam Iver with BTIG. Alan is now open.

Operator: Thank you. The final question comes from the line of Sam Eiber with BTIG. Your line is now open.

Speaker #6: Hi. Good morning. Thanks for taking the questions here. Maybe I can start on the Greenbrook side really strong quarter. On that side of the business, I'm wondering if you could help parse out maybe some of the underlying trends you're seeing on this bravado side versus the TMS side of the business.

Sam Eiber: Hi. Good morning. Thanks for taking the questions here. Maybe I can start on the Greenbrook side. A really strong quarter on that side of the business. Dan, wondering if you could help parse out maybe some of the underlying trends you are seeing on the SPRAVATO side versus the TMS side of the business. Then, just as I think about Compass and psilocybin entering the market perhaps next year, maybe just talk about how your model is set up best by offering SPRAVATO, TMS, psilocybin, and why that is the best model for patients.

Speaker #6: And then just as I think about Compass until a cyber entering entering the market, perhaps next year, maybe just talk about how your model is set up best by offering sort of auto TMS, psilocybin, and why that's the best model for patients.

Speaker #5: Yeah. So just making a quick note here. So I think first of all, on the Spravato versus TMS, we saw a bit more strength probably from TMS even or from Spravato even than TMS, but I think the fact that the overall business is growing is just a good reflection of the fact that Greenbrook's becoming an increasing destination of choice for referral sources.

Dan Reuvers: Yeah. Just making a quick note here. I think first of all, on the SPRAVATO versus TMS, we saw a bit more strength, probably from SPRAVATO even than TMS. But I think the fact that the overall business is growing is just a good reflection of the fact that Greenbrook is becoming an increasing destination of choice for referral sources. The SPRAVATO business is certainly more durable, as I think I have alluded to in the past. The duration between treatments, even after an initial round, continues to be more sustainable. I guess that is good for us. From a patient standpoint, it means they have to revisit us a bit more frequently. So those patients tend to stay more active for a longer period of time within our network.

Speaker #5: The Spravato business is certainly more durable as I think I've alluded to in the past. The duration between treatments, even after an initial round, continues to be more sustainable.

Speaker #5: I guess that's good for us from a patient standpoint. It means they have to revisit us a bit more frequently, so those patients tend to stay more active for a longer period of time within our network.

Speaker #5: I think on the Compass side, I think there's a number of things that I alluded to in our comments earlier that really position us well.

Dan Reuvers: I think on the Compass side, I think there are a number of things that I alluded to in our comments earlier that really position us well. I think we are really poised to be a first-mover benefactor, just in part because of the close collaboration we have had with them and some of the preparation benefits, but also the infrastructure that we talked about that already exists because of our SPRAVATO participation. The REMS certification, the rooms setups, the capacity availability, all of those things, I think, lend themselves to positioning us in a pole position. I think the other one, Sam, is a little bit about your question about the blend. We really want to position ourselves with referral sources as the destination of choice for whatever intervention is best suited for that patient within the interventional psychiatry scope.

Speaker #5: I think we're really poised to be a first-mover benefactor, just in part because of the close collaboration we've had with them and some of the preparation benefits, but also the infrastructure that we've talked about that already exists because of our Spravato participation.

Speaker #5: REMS certification, the rooms setups, the capacity availability, all of those things I think lend themselves to positioning us in kind of a pole position.

Speaker #5: And I think the other one Sam is a little bit about kind of your question about the blend. We really want to position ourselves with referral sources as the destination of choice for whatever intervention is best suited for that patient within the interventional psychiatry scope.

Speaker #5: And I think that we've already done that with TMS, with Spravato, we look forward to doing it with Compass. And I think as additional new therapeutics come out, we are positioning ourselves both infrastructure and on brand that we really want to be the destination that they can entrust their patients the fact that we don't do medical management and psychotherapy also gives those referral sources the confidence that they can send their patients to us.

Dan Reuvers: I think that we've already done that with TMS, with SPRAVATO. We look forward to doing it with Compass. I think as additional new therapeutics come out, we are positioning ourselves, both infrastructure and on brand, that we really want to be the destination that they can entrust their patients. The fact that we don't do medical management and psychotherapy also gives those referral sources the confidence that they can send their patients to us and know that they'll get them back. I think all of those are important parts of the ecosystem we're trying to build.

Speaker #5: And know that they'll get them back. And I think all of those are important parts of kind of the ecosystem we're trying to build.

Speaker #6: Yeah, that's really helpful, Dan. Thanks for the added color there. Maybe I can just use a follow-up here on some of the comments around different sales methods.

Sam Eiber: Yeah, that's really helpful, Dan. Thanks for the added color there. Maybe I can just use a follow-up here on some of the comments around different sales methods you're going to be evaluating with regard to field reps and direct-to-consumer spending. Are there certain KPIs that you'll be tracking or that we should be mindful of as you, I guess, evaluate efficiently getting more patients through the door here?

Speaker #6: You're going to be evaluating with regard to field reps and direct-to-consumer spending. Are there certain KPIs that you'll be tracking or that we should be mindful of as you I guess evaluate efficiently getting more patients through the door here?

Speaker #5: Yeah. I think so externally, KPIs, I think you can ultimately look at our operating expenses, of course. Internally, patient acquisition cost is one that we're taking a more scrutinizing look at.

Dan Reuvers: Yeah. So externally, KPIs, I think you can ultimately look at our operating expenses, of course. Internally, patient acquisition cost is one that we're taking a more scrutinizing look at. I can say quite confidently that the account managers that support the Greenbrook community are proving to be a very effective source for referral generation. I think we want to take a closer look at the balance in spend between our field team and some of our direct-to-consumer ad spend, along with some of the other things that we do from a peer-to-peer education. We're just trying to be a lot more thoughtful about trying to evaluate what are each one of those cost and which ones are returning the most effectively.

Speaker #5: And I can say quite confidently that the account managers that support the Greenbrook community are proving to be a very effective source for referral generation.

Speaker #5: I think we want to take a closer look at the balance in spend between our field team and some of our direct-to-consumer ad spend along with some of the other things that we do from a peer-to-peer education.

Speaker #5: And we're just trying to be a lot more thoughtful about really evaluating what each one of those cost, and which ones are returning the most effectively.

Speaker #5: And I would expect that we will probably pull and push on some levers, try and rebalance our spend in the most effective paths, and at the expense of some of the others.

Dan Reuvers: I would expect that we will probably pull and push on some levers, try and rebalance our spend in the most effective paths and at the expense of some of the others. Some of that work continues to move on. There's a lot of analytics that we're working on, but at the end of the day, I think it really comes down to our patient acquisition costs and what's the most efficient way to get the right patient who can benefit from our therapies in a chair.

Speaker #5: So some of that work continued to go on. There’s a lot of analytics that we’re working on. But at the end of the day, I think it really comes down to our patient acquisition cost and what’s the most efficient way to get the right patient who can benefit from our therapies in a chair.

Speaker #6: Okay. Very good. Thanks for taking the questions.

Sam Eiber: Okay. Very good. Thanks for taking the questions.

Speaker #2: Thank you. And I'm sure no further questions in the queue. I will now turn the call back over to Mr. Dan Rivers for any closing comments.

Operator: Thank you. I am showing no further questions in the queue. I will now turn the call back over to Mr. Dan Reuvers for any closing comments.

Speaker #5: Thanks, operator. And thank you to everyone for joining today's call. We really look forward to updating you on our progress during our next quarterly call.

Dan Reuvers: Thanks, operator. Thank you to everyone for joining today's call. We really look forward to updating you on our progress during our next quarterly call, and hope everybody has a good rest of the summer. Thank you.

Speaker #5: And hope everybody has a good rest of the summer. Thank you.

Operator: This concludes today's conference call. Thank you for your participation, and you may now disconnect.

Q2 2026 Neuronetics Inc Earnings Call

Request DemoDemo

Neuronetics

Earnings